US FDA okays Merck's new once-daily HIV pill

The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push

The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform

Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease

By cutting pain crises & boosting haemoglobin

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev

Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion

A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline

Leinco and CellCarta team up to power next-gen proteomics for cancer and targeted therapies

Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research

Zyax Chem takes 26% stake in Gaymed Labs

Targets high-growth eye care expansion push

Merck unveils bio-based HPLC solvents slashing CO2 emissions by up to 29%

Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials

India–UK life sciences research to advance through new cross-border innovation corridor

C-CAMP–Imperial College London partnership to boost biotech research, startup exchange, and translational innovation through a five-year collaboration